Synthesis and biological evaluation of 2-alkylaminoethyl-1,1-bisphosphonic acids against Trypanosoma cruzi and Toxoplasma gondii targeting farnesyl diphosphate synthase

The effect of a series of 2-alkylaminoethyl-1,1-bisphosphonic acids against proliferation of the clinically more relevant form of Trypanosoma cruzi, the etiologic agent of American trypanosomiasis (Chagas' disease), and against tachyzoites of Toxoplasma gondii has been studied. Most of these dr...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autor principal: Szajnman, S.H
Otros Autores: García Liñares, G.E, Li, Z.-H, Jiang, C., Galizzi, M., Bontempi, E.J, Ferella, M., Moreno, S.N.J, Docampo, R., Rodriguez, J.B
Formato: Capítulo de libro
Lenguaje:Inglés
Publicado: 2008
Acceso en línea:Registro en Scopus
DOI
Handle
Registro en la Biblioteca Digital
Aporte de:Registro referencial: Solicitar el recurso aquí
LEADER 12521caa a22016937a 4500
001 PAPER-6034
003 AR-BaUEN
005 20230518203543.0
008 190411s2008 xx ||||fo|||| 00| 0 eng|d
024 7 |2 scopus  |a 2-s2.0-41249085709 
024 7 |2 cas  |a geranyltransferase, 37277-79-5, 50812-36-7; Antiprotozoal Agents; Diphosphonates; Enzyme Inhibitors; Geranyltranstransferase, 2.5.1.10 
040 |a Scopus  |b spa  |c AR-BaUEN  |d AR-BaUEN 
030 |a BMECE 
100 1 |a Szajnman, S.H. 
245 1 0 |a Synthesis and biological evaluation of 2-alkylaminoethyl-1,1-bisphosphonic acids against Trypanosoma cruzi and Toxoplasma gondii targeting farnesyl diphosphate synthase 
260 |c 2008 
270 1 0 |m Rodriguez, J.B.; Departamento de Química Orgánica and UMYMFOR (CONICET-FCEyN), Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Pabellon 2, Ciudad Universitaria, C1428EHA Buenos Aires, Argentina; email: jbr@qo.fcen.uba.ar 
506 |2 openaire  |e Política editorial 
504 |a Urbina, J.A., Docampo, R., (2003) Trends Parasitol., 19, pp. 495-501 
504 |a Moncayo, A. In Eleventh Programme Report of the UNDP/World Bank/WHO Special Program for Research and Training in Tropical Diseases (TDR). World Health Organization: Geneva, 1995, pp 67-75; Docampo, R., (2001) Curr. Pharm. Des., 7, pp. 1157-1164 
504 |a Brener, Z., (1973) Annu. Rev. Microbiol., 27, pp. 347-382 
504 |a De Souza, W., (1984) Int. Rev. Cytol., 86, pp. 197-283 
504 |a García Liñares, G., Ravaschino, E.L., Rodriguez, J.B., (2006) Curr. Med. Chem., 13, pp. 335-360 
504 |a Galel, S.A., Kirchhoff, L.V., (1996) Transfusion, 36, pp. 227-231 
504 |a Nussenzweig, V., Sonntag, R., Biancalana, A., Pedreira de Fleitas, J.L., Amato Neto, V., Kloetzel, J., (1953) Hospital (Rio de Janeiro), 44, pp. 731-744 
504 |a Docampo, R., Moreno, S.N.J., (1985) Rev. Biochem. Toxicol., 7, pp. 159-204 
504 |a De Castro, S.L., (1993) Acta Trop., 53, pp. 83-98 
504 |a Urbina, J.A., (2002) Curr. Pharm. Des., 8, pp. 287-295 
504 |a Docampo, R., Moreno, S.N.J., (2001) Curr. Drug Targets Infect. Disord., 1, pp. 51-61 
504 |a Gelb, M.H., Van Voorhis, W.C., Buckner, F.S., Yokoyama, K., Eastman, R., Carpenter, E.P., Panethymitaki, C., Smith, D.F., (2003) Mol. Biochem. Parasitol., 126, pp. 155-163 
504 |a Ferella, M., Montalvetti, A., Rohloff, P., Miranda, K., Fang, J., Reina, S., Kawamukai, M., Bontempi, E.J., (2006) J. Biol. Chem., 281, pp. 39339-39348 
504 |a Gabelli, S.B., McLellan, J.S., Montalvetti, A., Oldfield, E., Docampo, R., Amzel, L.M., (2006) Proteins, 62, pp. 80-88 
504 |a Guo, R.-T., Cao, R., Liang, P.-H., Ko, T.-P., Chang, T.-H., Hudock, M.P., Jeng, W.-Y., Wang, A.H.-J., (2007) Proc. Natl. Acad. Sci. U.S.A., 104, pp. 10022-10027 
504 |a Reszka, A.A., Rodan, G.A., (2004) Mini Rev. Med. Chem., 4, pp. 711-719 
504 |a Urbina, J.A., Moreno, B., Vierkotter, S., Oldfield, E., Payares, G., Sanoja, C., Bailey, B.N., Docampo, R., (1999) J. Biol. Chem., 274, pp. 33609-33615 
504 |a Hughes, D.E., Wright, K.R., Uy, H.L., Sasaki, A., Yoneda, T., Roodman, G.D., Mundy, G.R., Boyce, B.F., (1995) J. Bone Mineral. Res., 10, pp. 1478-1487 
504 |a Rogers, M.J., Frith, J.C., Luckman, S.P., Coxon, F.P., Benford, H.L., Monkkonen, J., Auriola, S., Russell, R.G., (1999) Bone, 24, pp. 73S-79S 
504 |a Martin, M.B., Sanders, J.M., Kendrick, H., De Luca-Fradley, K., Lewis, J.C., Grimley, J.S., Van Brussel, E.M., Oldfield, E., (2002) J. Med. Chem., 45, pp. 2904-2914 
504 |a Ghosh, S., Chan, J.M., Lea, C.R., Meints, G.A., Lewis, J.C., Tovian, Z.S., Flessner, R.M., Oldfield, E., (2004) J. Med. Chem., 47, pp. 175-187 
504 |a Szajnman, S.H., Bailey, B.N., Docampo, R., Rodriguez, J.B., (2001) Bioorg. Med. Chem. Lett., 11, pp. 789-792 
504 |a Szajnman, S.H., Montalvetti, A., Wang, Y., Docampo, R., Rodriguez, J.B., (2003) Bioorg. Med. Chem. Lett., 13, pp. 3231-3235 
504 |a Szajnman, S.H., Ravaschino, E.L., Docampo, R., Rodriguez, J.B., (2005) Bioorg. Med. Chem. Lett., 15, pp. 4685-4690 
504 |a Ling, Y., Sahota, G., Odeh, S., Chan, J.M.W., Araujo, F.G., Moreno, S.N.J., Oldfield, E., (2005) J. Med. Chem., 48, pp. 3130-3140 
504 |a Martin, M.B., Grimley, J.S., Lewis, J.C., Heath III, H.T., Bailey, B.N., Kendrick, H., Yardley, V., Oldfield, E., (2001) J. Med. Chem., 44, pp. 909-916 
504 |a Bouzahzah, B., Jelicks, L.A., Morris, S.A., Weiss, L.M., Tanowitz, H.B., (2005) Parasitol. Res., 96, pp. 184-187 
504 |a Hosfield, D.J., Zhang, Y., Dougan, D.R., Broun, A., Tari, L.W., Swanson, R.V., Finn, J., (2003) J. Biol. Chem., 278, pp. 18401-18407 
504 |a Tarshis, L.C., Proteau, P.J., Kellogg, B.A., Sacchettini, J.C., Poulter, C.D., (1996) Proc. Natl. Acad. Sci. U.S.A., 93, pp. 15018-15023 
504 |a Montalvetti, A., Bailey, B.N., Martin, M.B., Severin, G.W., Oldfield, E., Docampo, R., (2001) J. Biol. Chem., 276, pp. 33930-33937 
504 |a Szajnman, S.H., García Liñares, G.E., Moro, P., Rodríguez, J.B., (2005) Eur. J. Org. Chem., pp. 3687-3696 
504 |a Degenhardt, C.R., Burdsall, D.C., (1986) J. Org. Chem., 51, pp. 3488-3490 
504 |a Wasielewski, C., Antczak, K., (1981) Synthesis, pp. 540-541 
504 |a Cromartie, T. H.; Fisher, K. J. PCT Int. Appl. 1995, WO 95/34207 A1; Fisher, K. J.; Woolard, F. X.; Leadbetter, M. R.; Gerdes, J. M. 1998, U.S. Patent 5,728,650; Cinque, G.M., Szajnman, S.H., Zhong, L., Docampo, R., Rodriguez, J.B., Gros, E.G., (1998) J. Med. Chem., 41, pp. 1540-1554 
504 |a Rodrigues, C.O., Scott, D.A., Bailey, B., de Souza, W., Benchimol, M., Moreno, B., Urbina, J.A., Moreno, S.N.J., (2000) Biochem. J., 349, pp. 737-745 
504 |a Urbina, J.A., Concepcion, J.L., Montalvetti, A., Rodriguez, J.B., Docampo, R., (2003) Antimicrob. Agents Chemother., 47, pp. 2047-2050 
504 |a Ling, Y., Li, Z.-H., Miranda, K., Oldfield, E., Moreno, S.N.J., (2007) J. Biol. Chem., 282, pp. 30804-30816 
504 |a Ravaschino, E.L., Docampo, R., Rodriguez, J.B., (2006) J. Med. Chem., 49, pp. 426-435 
504 |a Yan, W., Moreno, S.N., (1998) J. Immunol. Methods, 220, pp. 123-128 
504 |a Gubbels, M.J., Li, C., Striepen, B., (2003) Antimicrob. Agents Chemother., 47, pp. 309-316 
504 |a Montalvetti, A., Fernandez, A., Sanders, J.M., Ghosh, S., Van Brussel, E., Oldfield, E., Docampo, R., (2003) J. Biol. Chem., 278, pp. 17075-17083 
504 |a Ogura, K., Nishino, T., Shinka, T., Seto, S., (1985) Methods Enzymol., 110, pp. 167-171 
504 |a Rilling, H.C., (1985) Methods Enzymol., 110, pp. 145-152 
520 3 |a The effect of a series of 2-alkylaminoethyl-1,1-bisphosphonic acids against proliferation of the clinically more relevant form of Trypanosoma cruzi, the etiologic agent of American trypanosomiasis (Chagas' disease), and against tachyzoites of Toxoplasma gondii has been studied. Most of these drugs exhibited an extremely potent inhibitory action against the intracellular form of T. cruzi, exhibiting IC50 values at the low micromolar level. This cellular activity was associated with a strong inhibition of the enzymatic activity of T. cruzi farnesyl diphosphate synthase (TcFPPS), which constitutes a valid target for Chagas' disease chemotherapy. Compound 17 was an effective agent against amastigotes exhibiting an IC50 value of 0.84 μM, while this compound showed an IC50 value of 0.49 μM against the target enzyme TcFPPS. Interestingly, compound 19 was very effective against both T. cruzi and T. gondii exhibiting IC50 values of 4.1 μM and 2.6 μM, respectively. In this case, 19 inhibited at least two different enzymes of T. cruzi (TcFPPS and solanesyl diphosphate synthase (TcSPPS); 1.01 μM and 0.25 μM, respectively), while it inhibited TgFPPS in T. gondii. In general, this family of drugs was less effective against the activity of T. cruzi SPPS and against T. gondii growth in vitro. As bisphosphonate-containing compounds are FDA-approved drugs for the treatment of bone resorption disorders, their potential low toxicity makes them good candidates to control tropical diseases. © 2007 Elsevier Ltd. All rights reserved.  |l eng 
593 |a Departamento de Química Orgánica and UMYMFOR (CONICET-FCEyN), Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Pabellon 2, Ciudad Universitaria, C1428EHA Buenos Aires, Argentina 
593 |a Center for Tropical and Emerging Global Diseases, Department of Cellular Biology, University of Georgia, Athens, GA 30602, United States 
593 |a Instituto Nacional de Parasitologia Dr. Mario Fatala Chabén, Administración Nacional de Laboratorios e Institutos de Salud, Ministerio de Salud, Paseo Colón 568, Buenos Aires C1063ACT, Argentina 
690 1 0 |a BISPHOSPHONATES 
690 1 0 |a CHAGAS' DISEASE 
690 1 0 |a FARNESYL DIPHOSPHATE SYNTHASE 
690 1 0 |a SOLANESYL DIPHOSPHATE SYNTHASE 
690 1 0 |a TOXOPLASMA GONDII 
690 1 0 |a TOXOPLASMOSIS 
690 1 0 |a TRYPANOSOMA CRUZI 
690 1 0 |a 1 [(2 METHYLPROP 1 YLAMINO)ETHYL] 1,1 BISPHOSPHONIC ACID 
690 1 0 |a 1 [(2 PIPERIDIN 1 YLAMINO)ETHYL] 1,1 BISPHOSPHONIC ACID 
690 1 0 |a 1 [(2 PYRROLIDIN 1 YLAMINO)ETHYL] 1,1 BISPHOSPHONIC ACID 
690 1 0 |a 1 [(3 METHYL BUT 1 YLAMINO)ETHYL] 1,1 BISPHOSPHONIC ACID 
690 1 0 |a 1 [(BUT 2 YLAMINO)ETHYL] 1,1 BISPHOSPHONIC ACID 
690 1 0 |a 1 [(CYCLOHEXYLAMINO)ETHYL] 1,1 BISPHOSPHONIC ACID 
690 1 0 |a 1 [(N BUT 1 YLAMINO)ETHYL] 1,1 BISPHOSPHONIC ACID 
690 1 0 |a 1 [(N HEPT 1 YLAMINO)ETHYL] 1,1 BISPHOSPHONIC ACID 
690 1 0 |a 1 [(N HEX 1 YLAMINO)ETHYL] 1,1 BISPHOSPHONIC ACID 
690 1 0 |a 1 [(N OCT 1 YLAMINO)ETHYL] 1,1 BISPHOSPHONIC ACID 
690 1 0 |a 1 [(N PENT 1 YLAMINO)ETHYL] 1,1 BISPHOSPHONIC ACID 
690 1 0 |a 1 [(PROP 1 YLAMINO)ETHYL] 1,1 BISPHOSPHONIC ACID 
690 1 0 |a 1 [(PROP 2 YLAMINO)ETHYL] 1,1 BISPHOSPHONIC ACID 
690 1 0 |a 1 [(TERT BUTYLAMINO)ETHYL] 1,1 BISPHOSPHONIC ACID 
690 1 0 |a ANTIPROTOZOAL AGENT 
690 1 0 |a BISPHOSPHONIC ACID DERIVATIVE 
690 1 0 |a GERANYLTRANSFERASE 
690 1 0 |a UNCLASSIFIED DRUG 
690 1 0 |a AMASTIGOTE 
690 1 0 |a ANTIPROTOZOAL ACTIVITY 
690 1 0 |a ARTICLE 
690 1 0 |a BIOLOGICAL ACTIVITY 
690 1 0 |a CHAGAS DISEASE 
690 1 0 |a COMPARATIVE STUDY 
690 1 0 |a CONCENTRATION RESPONSE 
690 1 0 |a CONTROLLED STUDY 
690 1 0 |a DRUG INDICATION 
690 1 0 |a DRUG MECHANISM 
690 1 0 |a DRUG POTENCY 
690 1 0 |a DRUG SAFETY 
690 1 0 |a DRUG SCREENING 
690 1 0 |a DRUG SYNTHESIS 
690 1 0 |a DRUG TARGETING 
690 1 0 |a ENZYME ACTIVITY 
690 1 0 |a ENZYME INHIBITION 
690 1 0 |a FOOD AND DRUG ADMINISTRATION 
690 1 0 |a GROWTH INHIBITION 
690 1 0 |a IC 50 
690 1 0 |a NONHUMAN 
690 1 0 |a PARASITE CULTIVATION 
690 1 0 |a TOXICITY TESTING 
690 1 0 |a TOXOPLASMA GONDII 
690 1 0 |a TRYPANOSOMA CRUZI 
690 1 0 |a ANIMALS 
690 1 0 |a ANTIPROTOZOAL AGENTS 
690 1 0 |a DIPHOSPHONATES 
690 1 0 |a ENZYME INHIBITORS 
690 1 0 |a GERANYLTRANSTRANSFERASE 
690 1 0 |a INHIBITORY CONCENTRATION 50 
690 1 0 |a STRUCTURE-ACTIVITY RELATIONSHIP 
690 1 0 |a TOXOPLASMA 
690 1 0 |a TRYPANOSOMA CRUZI 
690 1 0 |a TOXOPLASMA GONDII 
690 1 0 |a TRYPANOSOMA CRUZI 
700 1 |a García Liñares, G.E. 
700 1 |a Li, Z.-H. 
700 1 |a Jiang, C. 
700 1 |a Galizzi, M. 
700 1 |a Bontempi, E.J. 
700 1 |a Ferella, M. 
700 1 |a Moreno, S.N.J. 
700 1 |a Docampo, R. 
700 1 |a Rodriguez, J.B. 
773 0 |d 2008  |g v. 16  |h pp. 3283-3290  |k n. 6  |p Bioorg. Med. Chem.  |x 09680896  |w (AR-BaUEN)CENRE-3989  |t Bioorganic and Medicinal Chemistry 
856 4 1 |u https://www.scopus.com/inward/record.uri?eid=2-s2.0-41249085709&doi=10.1016%2fj.bmc.2007.12.010&partnerID=40&md5=55843accc09932dca1273ac29e0d6e02  |y Registro en Scopus 
856 4 0 |u https://doi.org/10.1016/j.bmc.2007.12.010  |y DOI 
856 4 0 |u https://hdl.handle.net/20.500.12110/paper_09680896_v16_n6_p3283_Szajnman  |y Handle 
856 4 0 |u https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_09680896_v16_n6_p3283_Szajnman  |y Registro en la Biblioteca Digital 
961 |a paper_09680896_v16_n6_p3283_Szajnman  |b paper  |c PE 
962 |a info:eu-repo/semantics/article  |a info:ar-repo/semantics/artículo  |b info:eu-repo/semantics/publishedVersion 
963 |a VARI 
999 |c 66987